Magrolimab

ALX Oncology reported that its CD47-blocking agent in combination with Merck's Keytruda (pembrolizumab) failed to meet primary endpoints in two separate Phase II clinical trials.

The FDA has placed a partial clinical hold on trials of Gilead's magrolimab when used with azacitidine due to an imbalance in serious adverse events.

Patients with mNSCLC treated with magrolimab plus docetaxel showed improved outcomes correlated with peripheral CD47 saturation, according to a phase 2 trial biomarker analysis.

CD47-targeted therapies are emerging as a novel cancer immunotherapy approach, inhibiting the "don't eat me" signal that cancer cells use to evade immune surveillance.